Fig. 2
Luseogliflozin-mediated improvement in renal interstitial fibrosis at 1 week post ischemia/reperfusion (I/R) injury in mice. (a–c) Quantification of kidney mRNA levels of SM22 (a), COLA1 (b), and TGF (c) at 1 week post I/R injury. (d and e) Western blot analysis and quantification of αSMA expression in the kidney at 1 week post I/R injury in the following groups: vehicle-treated + sham-operated (n = 6), luseogliflozin-treated + sham-operated (n = 6), vehicle-treated + I/R-injured (n = 6), and luseogliflozin-treated + I/R-injured (n = 6). (f and g) Western blot analysis and quantification of collagen I expression in the kidney at 1 week post I/R injury in the following groups: vehicle-treated + sham-operated (n = 6), luseogliflozin-treated + sham-operated (n = 6), vehicle-treated + I/R-injured (n = 6), and luseogliflozin-treated + I/R-injured (n = 6). (h and i) Western blot analysis and quantification of fibronectin expression in the kidney at 1 week post I/R injury in the following groups: vehicle-treated + sham-operated (n = 6), luseogliflozin-treated + sham-operated (n = 6), vehicle-treated + I/R-injured (n = 6), and luseogliflozin-treated + I/R-injured (n = 6). (j–m) Histological findings and quantification of kidney sections stained with Sirius red (j, k) and Masson’s trichrome staining (l, m) at 1 week post I/R injury in the following groups: vehicle-treated + sham-operated (n = 5), luseogliflozin-treated + sham-operated (n = 5), vehicle-treated + I/R-injured (n = 10), and luseogliflozin-treated + I/R-injured (n = 10) ; *P < 0.05, **P < 0.01, as determined by one-way analysis of variance. n.s., not significant.
